EFPIA supports a new R&D model to tackle antimicrobial resistance

27 October 2011

A vote of the European Parliament’s Health Committee on the threat posed by antimicrobial resistance, to cope with this growing problem, calling for more research and better monitoring of the effects of antimicrobials, was adopted yesterday.

“The growing ineffectiveness of antibiotics is already a serious problem today and a potential health time bomb for the future. We need a clear European Union and international strategy to prevent misuse in agriculture and medicine, as well as to encourage the development of new antibiotics,” said Parliament’s Public Health Committee chairman Jo Leinen (S&D, DE).

Parliament wants the European Commission and EU member states to improve information to the public, around half of whom mistakenly believe that antibiotics can treat viruses or colds. MEPs also want the Commission to propose incentives to boost pharmaceutical research, which has produced few new antibiotics in recent decades.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical